Broadcast TV Adoption and Infrastructure Investment Model, 2006-2012 (Interactive Model)

A slice of the IT Services Contracts Database covering all deals signed in the month of July, 2008, delivered in an Excel datasheet

Report Highlights
This datasheet lists all the publicly announced IT services contract signings for the month of July, 2008
[Studien Infos ausblenden]

Table 1: Eli Lilly – PharmaVitae forecasts at a glance 7
Table 2: Eli Lilly key product developments, Q1–Q2 2008 26
Table 3: Eli Lilly product deals and alliances, Q1–Q2 2008 26
Table 4: Eli Lilly technology deals and alliances, Q1–Q2 2008 27
Table 5: Eli Lilly M&A activity, Q1–Q2 2008 27
Table 6: Eli Lilly company announcements, Q1–Q2 2008 28
Table 7: Eli Lilly future product milestones, 2008–10 28
Table 8: Eli Lilly product portfolio overview ($m), 2001–07 40
Table 9: Eli Lilly product portfolio overview ($m), 2007–13 42
Table 10: Eli Lilly product portfolio overview ($m), 2001–07 47
Table 11: Eli Lilly product portfolio overview ($m), 2007–13 50
Table 12: Eli Lilly portfolio overview by geographic region ($m), 2001–07 57
Table 13: Eli Lilly portfolio overview by geographic region ($m), 2007–13 59
Table 14: Eli Lilly launch portfolio overview ($m), 2007–13 63
Table 15: Eli Lilly core portfolio overview ($m), 2007–13 64
Table 16: Eli Lilly expiry portfolio overview ($m), 2007–13 65
Table 17: Eli Lilly portfolio overview by molecule type ($m), 2001–07 68
Table 18: Eli Lilly product portfolio overview by molecule type ($m), 2007–13 69
Table 19: Eli Lilly product portfolio overview by source ($m), 2001–07 72
Table 20: Eli Lilly product portfolio overview by source ($m), 2007–13 73
Table 21: Total Eli Lilly sales by business unit ($m), 2001–07 76
Table 22: Eli Lilly profit and loss account ($m), 2001–07 77
Table 23: Eli Lilly balance sheet ($m), 2001–07 79
Table 24: Eli Lilly operating revenue/cost analysis ($m), 2001–07 82
Table 25: Eli Lilly operating cost ratio analysis (% of total revenues), 2001–07 83
Table 26: Eli Lilly operating cost ratio analysis (% of total revenues), 2007–13 84
Table 27: Eli Lilly operating revenue/cost analysis ($m), 2007–13 87
Table 28: Eli Lilly capital employed ($m), 2001–07 89
Table 29: Eli Lilly EBIT return on capital employed ($m), 2001-07 91
Table 30: Eli Lilly EBIT pre-tax return/Capital employed driver analysis (%), 2001–07 92
Table 31: Eli Lilly market capitalization ($ billion), 2001–07 94
Table 32: Eli Lilly total shareholder returns (annual %), 2001–07 96
Table 33: Key products overview 98
Table 34: Cymbalta: overview 99
Table 35: Cymbalta: sales forecast ($m), 2007–13 100
Table 36: Zyprexa: overview 102
Table 37: Zyprexa: sales forecast ($m), 2007–13 103
Table 40: Byetta: overview 105
Table 41: Byetta: sales forecast ($m), 2007–13 106
Table 41: Byetta LAR: sales forecast ($m), 2007–13 106
Table 42: Alimta: overview 108
Table 43: Alimta: sales forecast ($m), 2007–13 109
Table 44: Gemzar: overview 110
Table 45: Gemzar: sales forecast ($m), 2007–13 111
Table 38: Effiant: overview 112
Table 39: Effiant: sales forecast ($m), 2007–13 113
Table 54: Eli Lilly’s R&D pipeline (Phase I–registration) 114
Table 55: Exchange rates, 2007 117

[Tabellenverzeichnis ausblenden]